Artesunate promoted anti-tumor immunity and overcame EGFR-TKI resistance in non-small-cell lung cancer by enhancing oncogenic TAZ degradation

Artesunate promoted anti-tumor immunity and overcame EGFR-TKI resistance in non-small-cell lung cancer by enhancing oncogenic TAZ degradation

Lung cancer is the leading cause of cancer-related death worldwide. The development of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and immune checkpoint inhibitors (ICIs) has brought favorable survival benefits to patients with non–small-cell lung cancer (NSCLC); unfortun...

Full description

Bibliographic Details
Main Authors:	Dai Cao, Die Chen, Jiang-Nan Xia, Wen-Yan Wang, Guo-Yuan Zhu, Li-Wen Chen, Chuantao Zhang, Bo Tan, Hui Li, Ying-Wei Li
Format:	Article
Language:	English
Published:	Elsevier 2022-11-01
Series:	Biomedicine & Pharmacotherapy
Subjects:	Anti-tumor immunity Artesunate EGFR-TKI resistance Non-small-cell lung cancer PD-L1 TAZ
Online Access:	http://www.sciencedirect.com/science/article/pii/S0753332222010940

Similar Items

Combining EGFR-TKI With SAHA Overcomes EGFR-TKI-Acquired Resistance by Reducing the Protective Autophagy in Non-Small Cell Lung Cancer
by: Peijun Cao, et al.
Published: (2022-03-01)

Radiolabeled EGFR TKI as predictive imaging biomarkers in NSCLC patients – an overview
by: Eveline Van De Stadt, et al.
Published: (2022-10-01)

A Large Real-World Study on the Effectiveness of the Combined Inhibition of EGFR and MET in EGFR-Mutant Non-Small-Cell Lung Cancer After Development of EGFR-TKI Resistance
by: Li Liu, et al.
Published: (2021-10-01)

Effectiveness of EGFR‐TKI rechallenge immediately after PD‐1 blockade failure
by: Kyoichi Kaira, et al.
Published: (2021-03-01)

Clinical Developments for the EGFR-TKI Combined with Radiotherapy in Advanced Non-small Cell Lung Cancer
by: Xianan LI, et al.
Published: (2014-04-01)

Therapeutic effect of whole brain radiotherapy on advanced NSCLC between EGFR TKI-naïve and TKI-resistant
by: Lihao Zhao, et al.
Published: (2019-12-01)

First-Generation EGFR-TKI Plus Chemotherapy Versus EGFR-TKI Alone as First-Line Treatment in Advanced NSCLC With EGFR Activating Mutation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
by: Qiang Wu, et al.
Published: (2021-04-01)

EGFR‐mutated stage IV non‐small cell lung cancer: What is the role of radiotherapy combined with TKI?
by: Bailong Liu, et al.
Published: (2021-09-01)

The prognostic impact of neutrophil to lymphocyte ratio in advanced non-small-cell lung cancer patients treated with EGFR TKI
by: Phan TT, et al.
Published: (2018-11-01)

Mechanisms of EGFR-TKI-Induced Apoptosis and Strategies Targeting Apoptosis in EGFR-Mutated Non-Small Cell Lung Cancer
by: Shigetoshi Nishihara, et al.
Published: (2022-11-01)

Long-Term Clinical Benefit in EGFR-Mutant Lung Adenocarcinoma With Local Squamous Cell Carcinoma Transformation After EGFR TKI Resistance: A Case Report
by: Junru Ye, et al.
Published: (2022-05-01)

Construction of the model for predicting prognosis by key genes regulating EGFR-TKI resistance
by: Jinke Zhuge, et al.
Published: (2022-11-01)

Emerging Role of Noncoding RNAs in EGFR TKI-Resistant Lung Cancer
by: Jingwei Li, et al.
Published: (2022-09-01)

Molecular Mechanism and Progression of Primary Resistance to EGFR-TKI - Analysis of 2 Cases
by: Meirong LIU, et al.
Published: (2019-01-01)

Resistance to Both Chemotherapy and EGFR-TKI in Small Cell Lung Cancer With EGFR 19-Del Mutation: A Case Report
by: Lingfei Wang, et al.
Published: (2020-07-01)

Activated TAZ induces liver cancer in collaboration with EGFR/HER2 signaling pathways
by: Hyuk Moon, et al.
Published: (2022-04-01)

The Presence of EGFR T790M in TKI-Naïve Lung Cancer Samples of Patients Who Developed a T790M-Positive Relapse on First or Second Generation TKI Is Rare
by: Weiting Li, et al.
Published: (2022-07-01)

Abnormally activated OPN/integrin αVβ3/FAK signalling is responsible for EGFR-TKI resistance in EGFR mutant non-small-cell lung cancer
by: Yulong Fu, et al.
Published: (2020-12-01)

Histological Transformation after Acquired Resistance to the Third-Generation EGFR-TKI in Patients with Advanced <i>EGFR</i>-Mutant Lung Adenocarcinoma
by: Po-Hsin Lee, et al.
Published: (2022-07-01)

Suppression of Mig-6 overcomes the acquired EGFR-TKI resistance of lung adenocarcinoma
by: Da Hyun Kang, et al.
Published: (2020-06-01)

Is ICI-based therapy better than chemotherapy for metastatic NSCLC patients who develop EGFR-TKI resistance? A real-world investigation
by: Yajie Cheng, et al.
Published: (2022-08-01)

Relationship between ID1 and EGFR-TKI Resistance  in Non-small Cell Lung Cancer
by: Yuchen BAO, et al.
Published: (2016-12-01)

STE029 Overcomes EGFR-TKI Resistance in Human Lung Adenocarcinoma
by: Lin HUANG, et al.
Published: (2022-11-01)

Apatinib added when NSCLC patients get slow progression with EGFR‐TKI: A prospective, single‐arm study
by: Minghui Liu, et al.
Published: (2023-12-01)

Research Progress of Mechanisms on Intracranial Metastasis of Non-small Cell Lung Cancer after Clinical Benefit from EGFR-TKI
by: Juan JIANG, et al.
Published: (2015-08-01)

ORIENT-31 as the Sakigake “Charging Samurai” Born of IMpower150 but Will MARIPOSA-2 IMPRESS in the “Meiji Modernization” of Post-3G EGFR TKI Progression?
by: Nagasaka M, et al.
Published: (2022-03-01)

IL-22 Confers EGFR-TKI Resistance in NSCLC via the AKT and ERK Signaling Pathways
by: Xiaomeng Wang, et al.
Published: (2019-11-01)

Rechallenge with EGFR-TKI after failure of immunotherapy is considered an effective treatment for advanced lung adenocarcinoma patients with EGFR exon 19 deletion: a case report
by: Shubin Chen, et al.
Published: (2023-06-01)

The Effects of Artesunate on the Expression of EGFR and ABCG2 in A549 Human Lung Cancer Cells and a Xenograft Model
by: Zheng-Tang Chen, et al.
Published: (2011-12-01)

Research Progress of HGF/MET Signaling Pathway in EGFR-TKI Resistance  in Non-small Cell Lung Cancer
by: Shilong SONG, et al.
Published: (2014-10-01)

Increased expression of TAZ and associated upregulation of PD-L1 in cervical cancer
by: Yanyan Han, et al.
Published: (2021-11-01)

Chinese Herbal Medicine Combined With EGFR-TKI in EGFR Mutation-Positive Advanced Pulmonary Adenocarcinoma (CATLA): A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
by: Lijing Jiao, et al.
Published: (2019-07-01)

Concurrent use of anlotinib overcomes acquired resistance to EGFR‐TKI in patients with advanced EGFR‐mutant non‐small cell lung cancer
by: Chen Zhang, et al.
Published: (2021-10-01)

EGFR amplification is a putative resistance mechanism for NSCLC–LM patients with TKI therapy and is associated with poor outcome
by: Hainan Yang, et al.
Published: (2022-08-01)

Multiomics analysis revealed the mechanisms related to the enhancement of proliferation, metastasis and EGFR-TKI resistance in EGFR-mutant LUAD with ARID1A deficiency
by: Dantong Sun, et al.
Published: (2023-03-01)

Restricting Glutamine Uptake Enhances NSCLC Sensitivity to Third-Generation EGFR-TKI Almonertinib
by: Yaming Liu, et al.
Published: (2021-05-01)

Afatinib in EGFR TKI-Naïve Patients with Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Pooled Analysis of Three Phase IIIb Studies
by: Antonio Passaro, et al.
Published: (2021-07-01)

Physiologically Based Pharmacokinetic (PBPK) Modeling to Predict PET Image Quality of Three Generations EGFR TKI in Advanced-Stage NSCLC Patients
by: I. H. Bartelink, et al.
Published: (2022-06-01)

Dysregulated Metabolism in EGFR-TKI Drug Resistant Non-Small-Cell Lung Cancer: A Systematic Review
by: Julia Babuta, et al.
Published: (2022-07-01)

Cosuppression of NF-κB and AICDA Overcomes Acquired EGFR-TKI Resistance in Non-Small Cell Lung Cancer
by: Min-Kyung Yeo, et al.
Published: (2022-06-01)